Sonia Bakkour

Sonia Bakkour

Auto-generated profile, based on publicly available information

Sonia Bakkour

Vitalant Research Institute, San Francisco, California, United States

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in Cell Reports Medicine
Verified
Journal Article
Open access
CLClaire N. Levy
Claire N. Levy
SHSean M. Hughes
Sean M. Hughes
PRPavitra Roychoudhury
Pavitra Roychoudhury
DRDaniel B. Reeves
Daniel B. Reeves
CAChelsea Amstuz
Chelsea Amstuz
FHFlorian Hladik
Florian Hladik
Quantifying the replication-competent HIV reservoir is essential for evaluating curative strategies. Viral outgrowth assays (VOAs) underestimate the reservoir because they fail to induce all replication-competent proviruses. Single- or double-region HIV DNA assays overestimate it because they fail to exclude many defective proviruses. We designed two triplex droplet digital PCR assays, each with 2 unique targets and 1 in common, and normalize the results to PCR-based T cell counts. Both HIV assays are specific, sensitive, and reproducible. Together, they estimate the number of proviruses containing all five primer-probe regions. Our 5-target results are on average 12.1-fold higher than and correlate with paired quantitative VOA (Spearman's ρ = 0.48) but estimate a markedly smaller reservoir than previous DNA assays. In patients on antiretroviral therapy, decay rates in blood CD4+ T cells are faster for intact than for defective proviruses, and intact provirus frequencies are similar in mucosal and circulating T cells.

19 April 2022 in Transfusion
Verified
Journal Article
Closed access
CJCassandra D. Josephson
Cassandra D. Josephson
SGSimone Glynn
Simone Glynn
SMSunitha Mathew
Sunitha Mathew
RBRebecca Birch
Rebecca Birch
SBSonia Bakkour
Sonia Bakkour
SKSteve Kleinman
Steve Kleinman

27 May 2021 in Transfusion
Verified
Journal Article
Closed access
PDF file
SBSonia Bakkour
Sonia Bakkour
PSPaula Saá
Paula Saá
JGJamel A. Groves
Jamel A. Groves
LMLeilani Montalvo
Leilani Montalvo
CGClara Di Germanio
Clara Di Germanio
F(for the NHLBI Recipient Epidemiology and Donor Evaluation Study‐IV‐Pediatric (REDS‐IV‐P)
for the NHLBI Recipient Epidemiology and Donor Evaluation Study‐IV‐Pediatric (REDS‐IV‐P)

18 November 2020 in Journal of Clinical Microbiology
Verified
Journal Article
Open access
PDF file
JJJana L. Jacobs
Jana L. Jacobs
MTMelissa A. Tosiano
Melissa A. Tosiano
DKDianna L. Koontz
Dianna L. Koontz
BSBrittany Staines
Brittany Staines
AWAndrew Worlock
Andrew Worlock
JMJohn W. Mellors
John W. Mellors
Clearance of low-level viremia that persists in most HIV-1-positive individuals on antiretroviral therapy (ART) is an important milestone for efforts to cure HIV-1 infection. The level of persistent viremia on ART is generally below the lower limit of quantification (LOQ) of current FDA-cleared plasma HIV-1 RNA assays (20 to 40 copies/ml) but can be quantified by reverse transcriptase PCR (RT-PCR) assays with single-copy sensitivity. Such assays require multistep manual methods, and their low throughput limits the capacity to monitor the effects of interventions on persistent viremia. Recently, S. Bakkour, X. Deng, P. Bacchetti, E. Grebe, et al. (J Clin Microbiol 58:e01400-20, 2020, https://doi.org/10.1128/JCM.01400-20), reported the use of multiple replicates and Poisson statistics to infer HIV-1 RNA concentrations below the commercial LOQ of an automated platform (Hologic Panther Aptima). Here, we evaluate the detection and quantitation of low-level viremia using the following two adaptions of the automated platform: a multireplicate strategy (9×) and a concentrated single-replicate strategy in which 5 ml of plasma is concentrated by centrifugation (1×, concentrated). We compare these new methods to a recently reported manual integrase-targeting single-copy assay version 2 (iSCA v2). Using laboratory-generated HIV-1 RNA plasma samples at known concentrations, all three methods had similar sensitivity for HIV-1 RNA detection, although iSCA v2 was most sensitive (95% LOD, 2.3 copies/ml), 9× was marginally less sensitive (95% LOD, 3.0 copies/ml), and 1×, concentrated was least sensitive (95% LOD, 3.9 copies/ml). In contrast, for clinical plasma samples, 9× had greater sensitivity than iSCA v2 (82% of samples were quantifiable compared with 62% of samples by iSCA v2). These results support 9× as an acceptable high-throughput alternative to iSCA v2 for quantifying low-level viremia in individuals on ART.

24 August 2024 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
VAVivian I. Avelino-Silva
Vivian I. Avelino-Silva
MSMars Stone
Mars Stone
SBSonia Bakkour
Sonia Bakkour
CGClara Di Germanio
Clara Di Germanio
MSMichael Schmidt
Michael Schmidt
PNPhilip J. Norris
Philip J. Norris
Exposure to antiretrovirals at or early after HIV acquisition can suppress viral replication and blunt antibody (Ab) responses; a reduced HIV detectability could impact diagnosis and blood donation screening. We used three antigen (Ag)/Ab assays and one nucleic acid test (NAT) to analyze samples collected in pre-exposure prophylaxis (PrEP) trials (iPrEx; Partners PrEP) before infection detection by Ab-only rapid diagnostic tests (RDTs), and in early antiretroviral treatment (ART) initiation studies (RV254; SIPP). Reactivity using NAT and Ag/Ab assays in samples collected up to 8 weeks prior to the first reactive RDT from 251 PrEP trials participants varied between 49-61% for active PrEP users and between 27-37% for placebo users. Among RV254 participants, reactivity in Ag/Ab assays was <100% at all timepoints, and lower among those initiating ART earlier. Seroreversions occurred for 29% (16/55), and blood donation screening with NAT and Ag/Ab assays could have missed up to 36% (20/55) of RV254 participants. For SIPP participants, who started ART at later timepoints, Ag/Ab assays identified infections with no evidence of reactivity waning. PrEP and early ART initiation can delay or reduce HIV detectability. Considerations for the implementation of NAT and Ag/Ab tests in PrEP/PEP programs relying on Ab-only RDTs should be balanced according to feasibility and public health impact. While blood transfusion services using Ab-only RDTs for HIV screening should adopt higher sensitivity tests, surveillance and further research are needed to determine the need for novel HIV testing algorithms for those already using NAT and Ag/Ab screening assays.

2 April 2020 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
YGYanina Ghiglione
Yanina Ghiglione
MPMaría Laura Polo
María Laura Polo
AUAlejandra Urioste
Alejandra Urioste
ARAjantha Rhodes
Ajantha Rhodes
ACAlejandro Czernikier
Alejandro Czernikier
NLNatalia Laufer
Natalia Laufer
Hepatitis C virus (HCV) coinfection among people with human immunodeficiency virus (HIV) might perturb immune function and HIV persistence. We aimed to evaluate the impact of HCV clearance with direct-acting antivirals (DAAs) on immune activation and HIV persistence in HIV/HCV-coinfected individuals on antiretroviral therapy (ART). In a prospective observational study, ART-treated participants with HIV/HCV coinfection received sofosbuvir/daclatasvir ± ribavirin (n = 19). Blood samples were collected before DAA therapy, at the end of treatment, and 12 months after DAA termination (12MPT). T- and natural killer (NK)-cell phenotype, soluble plasma factors, cell-associated (CA)-HIV deoxyribonucleic acid (DNA) forms (total, integrated, 2LTR), CA-unspliced (US) and multiple-spliced ribonucleic acid (RNA), and plasma HIV RNA were evaluated. Hepatitis C virus clearance was associated with (1) a downmodulation of activation and exhaustion markers in CD4+, CD8+ T, and NK cells together with (2) decreased plasma levels of Interferon gamma-induced protein 10 (IP10), interleukin-8 (IL-8), soluble (s)CD163 and soluble intercellular adhesion molecule (sICAM). Cell-associated US HIV RNA was significantly higher at 12MPT compared to baseline, with no change in HIV DNA or plasma RNA. Elimination of HCV in HIV/HCV-coinfected individuals alters immune function and the transcriptional activity of latently infected cells. This report provides insights into the effects of HCV coinfection in HIV persistence and regards coinfected subjects as a population in which HIV remission might prove to be more challenging.